by Hanna | Oct 24, 2023 | Blog Post
A recent survey by the U.S. Chamber of Commerce sheds new light on the flaws of the Federal Trade Commission (FTC) and Department of Justice’s (DOJ) proposed approach to review and enforcement of mergers and acquisitions (M&A). The agencies’ two proposals – the...
by Hanna | Oct 12, 2023 | Blog Post
In a sharp departure from longstanding precedent, the Federal Trade Commission (FTC) and Department of Justice (DOJ) have proposed substantial changes to the existing guidelines and rules for antitrust enforcement. The set of proposals – specifically, the revised 2023...
by Hanna | Oct 12, 2023 | Blog Post
In a sharp departure from longstanding precedent, the Federal Trade Commission (FTC) and Department of Justice (DOJ) have proposed substantial changes to the existing guidelines and rules for antitrust enforcement. The set of proposals – specifically, the revised 2023...
by Hanna | Oct 11, 2023 | Blog Post
In a recent op-ed for Politico, Ankush Khardori, an attorney and former federal prosecutor for the Department of Justice (DOJ), points out the noticeable lack of evidence behind the DOJ and Federal Trade Commissions’ (FTC) proposed merger guidelines. ...
by Steve Strong | Oct 3, 2023 | Blog Post
Thousands of U.S. life sciences companies race every day to find better treatments and cures for a wide range of conditions and diseases. Within this diverse and dynamic life sciences ecosystem – made up of early-stage companies, large-scale entities, research...
by Steve Strong | Oct 3, 2023 | Blog Post
America has a long history of enacting sound, bipartisan policies that have created powerful incentives for life sciences innovators to invest in the costly, extensive research and development (R&D) process behind groundbreaking treatments and cures. These...
